Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Eliot N. Mostow MD, MPH Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · January 03, 2023

Early Itch Response With Abrocitinib Is Associated With Later Efficacy Outcomes in Patients With Moderate to Severe Atopic Dermatitis

American Journal of Clinical Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Matthew Zirwas MD

American Journal of Clinical Dermatology

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

Am J Clin Dermatol 2022 Dec 13;[EPub Ahead of Print], S Ständer, SG Kwatra, JI Silverberg, EL Simpson, JP Thyssen, G Yosipovitch, F Zhang, MC Cameron, RR Cella, H Valdez, M DiBonaventura, C Feeney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Early Itch Response With Abrocitinib Is Associated With Later Efficacy Outcomes in Patients With Moderate to Severe Atopic Dermatitis

Additional Info

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

Further Reading

Final Note From the Dermatology Editors

Outcomes of Treatment With 5-Fluorouracil 5% Cream in Patients With Squamous Cell Carcinoma In Situ

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Recently Updated